Unprejudiced healthcare
This is discrimination and a breach of human rights and humanitarian principles.
In an official note issued July 30, the hospital said it has closed its special medical clinic (SMC) to Cambodians, citing its heavy case load. This dubiously explained policy started yesterday and will run until Aug 10. The hospital will also stop hiring Khmer-speaking interpreters and will no longer provide accommodation for a group of volunteers who help with interpretation.
The hospital said any Cambodians currently receiving treatment at its inpatient ward will be subject to area restrictions.
Like some other hospitals in border provinces, the healthcare services at Sunprasitthiprasong -- a well-known regional hospital -- are popular among Cambodians living along the border, given their high quality.
It should be noted that the patients pay higher medical fees for treatment in the SMC ward. It is no secret that those higher up on the social ladder prefer to seek medical care at expensive private hospitals in Bangkok -- at least until the recent armed conflict broke out between Thailand and Cambodia.
Cambodian strongman Hun Sen, at the beginning of the conflict that stemmed from a clash on May 28 in the Chong Bok area of Ubon Ratchathani's Nam Yuen district, called for his compatriots to stop seeking medical services in Thailand.
This was part of the country's anti-Thai campaign as border checkpoints were closed one after another.
Sunpasitthiprasong Hospital said its decision will affect only new patients, whereas former or current patients can continue their treatment. It did not mention emergency cases, but it's understood that the new rule will also apply to them.
Such a decision seems to respond to noisy calls by some ultra-nationalist citizens -- as well as netizens engaging in wars of words -- over the past weeks amid the escalating armed conflict, that hospitals should stop serving Cambodian patients. Apparently, these narrow-minded racists misunderstand the nature of the SMC and the 30-baht healthcare scheme.
Needless to say, this policy will be played up by Cambodian media channels to cast Thailand in a bad light.
There are reports that the government and the Ad Hoc Centre for Thailand-Cambodia Border Situation gave a vague instruction to the hospital that it should adhere to the universal healthcare principle. The government must prohibit the hospital and other healthcare dispensers from adopting any policies based on racism.
After all, such discrimination is not acceptable. Breaching human rights principles will do more harm than good to Thailand's image and reputation. Such discrimination resulting from racism will unnecessarily fuel hatred among the peoples of the two countries, making reconciliation even harder.
Sunpasitthiprasong Hospital must not place itself in the middle of this conflict between the two governments. It must immediately review this racist policy, and not forget the mantra that sympathy must prevail for those in need of healthcare.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bangkok Post
2 hours ago
- Bangkok Post
Dangerous dreams: Inside internet's 'sleepmaxxing' craze
WASHINGTON - From mouth taping to rope-assisted neck swinging, a viral social media trend is promoting extreme bedtime routines that claim to deliver perfect sleep -- despite scant medical evidence and potential safety risks. Influencers on platforms including TikTok and X are fuelling a growing wellness obsession popularly known as "sleepmaxxing," a catch-all term for activities and products aimed at optimising sleep quality. The explosive rise of the trend -- generating tens of millions of posts -- underscores social media's power to legitimise unproven health practices, particularly as tech platforms scale back content moderation. One so-called insomnia cure involves people hanging by their necks with ropes or belts and swinging their bodies in the air. "Those who try it claim their sleep problems have significantly improved," said one clip on X that racked up more than 11 million views. Experts have raised alarm about the trick, following a Chinese state broadcaster's report that attributed at least one fatality in China last year to a similar "neck hanging" routine. Such sleepmaxxing techniques are "ridiculous, potentially harmful, and evidence-free," Timothy Caulfield, a misinformation expert from the University of Alberta in Canada, told AFP. "It is a good example of how social media can normalize the absurd." Another popular practice is taping of the mouth for sleep, promoted as a way to encourage nasal breathing. Influencers claim it offers broad benefits, from better sleep and improved oral health to reduced snoring. But a report from George Washington University found that most of these claims were not supported by medical research. Experts have also warned the practice could be dangerous, particularly for those suffering from sleep apnea, a condition that disrupts breathing during sleep. Other unfounded tricks touted by sleepmaxxing influencers include wearing blue- or red-tinted glasses, using weighted blankets, and eating two kiwis just before bed. ' Damaging' "My concern with the 'sleepmaxxing' trend -- particularly as it's presented on platforms like TikTok -- is that much of the advice being shared can be actively unhelpful, even damaging, for people struggling with real sleep issues," Kathryn Pinkham, a Britain-based insomnia specialist, told AFP. "While some of these tips might be harmless for people who generally sleep well, they can increase pressure and anxiety for those dealing with chronic insomnia or other persistent sleep problems." While sound and sufficient sleep is considered a cornerstone of good health, experts warn that the trend may be contributing to orthosomnia, an obsessive preoccupation with achieving perfect sleep. "The pressure to get perfect sleep is embedded in the sleepmaxxing culture," said Eric Zhou of Harvard Medical School. "While prioritising restful sleep is commendable, setting perfection as your goal is problematic. Even good sleepers vary from night to night." Pinkham added that poor sleep was often fuelled by the "anxiety to fix it," a fact largely unacknowledged by sleepmaxxing influencers. "The more we try to control sleep with hacks or rigid routines, the more vigilant and stressed we become -- paradoxically making sleep harder," Pinkham said. Beauty over health Many sleepmaxxing posts focus on enhancing physical appearance rather than improving health, reflecting an overlap with "looksmaxxing" –- another online trend that encourages unproven and sometimes dangerous techniques to boost sexual appeal. Some sleepmaxxing influencers have sought to profit from the trend's growing popularity, promoting products such as mouth tapes, sleep-enhancing drink powders, and "sleepmax gummies" containing melatonin. That may be in violation of legal norms in some countries like Britain, where melatonin is available only as a prescription drug. The American Academy of Sleep Medicine has recommended against using melatonin to treat insomnia in adults, citing inconsistent medical evidence regarding its effectiveness. Some medical experts also caution about the impact of the placebo effect on insomnia patients using sleep medication -- when people report real improvement after taking a fake or nonexistent treatment because of their beliefs. "Many of these tips come from non-experts and aren't grounded in clinical evidence," said Pinkham.
Bangkok Post
21 hours ago
- Bangkok Post
Chula Licenses Thai PD-1 Antibody to US Biopharma
Bangkok, August 6, 2025 — Chulalongkorn University has entered a landmark licensing agreement with US-based biopharmaceutical company OncoSynergy Inc., transferring the technology behind its innovative Thai-developed PD-1 antibody that could offer new hope in advancing next-generation cancer immunotherapy. The signing ceremony took place at the CU Innovation & IP Expo 2025, hosted by the university on August 4, 2025. Professor Dr. Wilert Puriwat, President of Chulalongkorn University, stated that OncoSynergy's decision to pursue the licensing agreement reflects its strong confidence in the quality and potential of Chula's PD-1 antibody research. This reaffirms Chulalongkorn's strategy not merely to keep pace with global trends, but to lead with innovations that meet world-class standards. Associate Professor Dr. Jittima Luckanagul, Executive Director of Strategic Research Advancement and the CU Innovation Hub, noted that this marks the first time a foreign company has licensed a novel drug innovation originating from Thailand. She added that OncoSynergy recognises the high potential of the university's research to advance into clinical trials and, ultimately, new drug registration an effort that may require an investment of between USD 500 million and 1 billion. In addition to the licensing fee, the university will gain valuable experience in the new drug registration process through collaborative research with OncoSynergy. The US-based company is a clinical-stage immuno-oncology firm dedicated to significantly improving outcomes for patients battling the most aggressive forms of cancer. Under this collaboration, if OncoSynergy successfully develops a new drug based on Chulalongkorn University's PD-1 antibody innovation, the parties have expressed a shared intention to explore mechanisms that would help ensure Thai patients have access to the therapy at a reasonable price. Dr. Trairak Pisitkun, Director of the Center of Excellence in Systems Biology at the Faculty of Medicine, Chulalongkorn University, shared that the centre began its research into cancer immunotherapy nearly a decade ago, supported by funding from the university, government agencies, and public donations. At the time, immunotherapy was an emerging and promising approach to harness the patient's immune system to fight cancer. Today, it has become a cornerstone of cancer treatment, encompassing three major modalities: cell-based therapies, cancer vaccines, and monoclonal antibodies many of which have since gained regulatory approval from health authorities worldwide. Dr. Trairak noted that preclinical studies of the novel PD-1 monoclonal antibody in multiple mouse tumour models demonstrated strong efficacy against solid tumours. Compared to commercially available PD-1 antibody drugs, the candidate exhibited superior PD-1 binding activity, with a lower dissociation constant (Kd), indicating tighter target engagement. In head-to-head assays, it outperformed most existing PD-1 antibodies in both binding affinity and PD-1/PD-L1 blockade. However, the path from successful animal studies to human clinical trials and ultimately to regulatory approval and commercial availability is long, complex, and capital-intensive. Chulalongkorn University anticipates that the full development process will take at least five years and require an investment of several hundred million US dollars. To accelerate this journey, the university has partnered with OncoSynergy, leveraging the company's experience in advancing novel immunotherapies toward clinical application. Immunotherapy is gaining global recognition for its ability to harness the body's own immune system to fight cancer, offering a more precise and potentially less toxic alternative to traditional treatments such as chemotherapy and radiotherapy. Dr. Trairak explained that PD-1 antibody drugs do not directly kill cancer cells, but instead work by blocking the PD-1 immune checkpoint a protein that suppresses the immune system's response to cancer. By inhibiting this pathway, the drugs help restore the immune system's ability to recognise and attack cancer cells. These antibodies are typically used in combination with other treatments including immunotherapies, surgery, radiation, or chemotherapy tailored to each patient's needs. He added that other forms of immunotherapy include CAR-T cell therapy, which engineers a patient's own T cells to better target cancer, and cancer vaccines, which train the immune system to recognise tumour-specific antigens for more effective elimination. The novel PD-1 antibody platform was a highlight of the CU Innovation & IP Expo 2025, underscoring Chulalongkorn University's growing leadership in cutting-edge cancer immunotherapy. The event showcased the university's ability to translate advanced biomedical research into globally competitive innovations. Professor Dr. Wilert Puriwat, President of Chulalongkorn University, emphasised that the CU Innovation Expo is more than a display of inventions it serves as a vital platform to build a strong research and innovation ecosystem in Thailand. 'This is not merely an exhibition of Chula's work,' he stated, 'but a call to action for Thai entrepreneurs to recognise the value of homegrown innovations that meet international standards of research and development.' The PD-1 antibody project represents a national milestone, demonstrating that Thailand is capable of producing world-class therapeutic innovations. The Expo featured over 50 standout innovations across five sectors food & agriculture, health & wellness, design, deep tech, and environment and attracted more than 200 companies. Chulalongkorn University is actively fostering partnerships between Thai companies, startups, and researchers through business matching and licensing opportunities. Partners benefit from unique advantages, including tax incentives and intellectual property privileges, while gaining access to world-class research teams at the university. 'We aim to position our research not only to keep pace with the world, but to deliver real impact practical innovations that serve the Thai people at every level of society,' Prof. Wilert concluded. 'This reflects the university's evolving role not just in education, but in driving economic growth and generating global value from Thai innovations.'
Bangkok Post
2 days ago
- Bangkok Post
Red Cross reps visit captured Cambodian soldiers
International Red Cross representatives on Tuesday visited 18 captured Cambodian soldiers and witnessed the good care being given them by the Thai army, according to the Royal Thai Army.. A statement testifying to this and describing the captives as "prisoners of war" was released on Tuesday by the army's spokesteam. Army and Foreign Affairs officials took Bangkok-based representatives of the International Committee of the Red Cross (ICRC) to visit the 18 Cambodian prisoners of war at a detention facility of the 2nd Army Region. The statement said the ICRC is an international humanitarian organisation that directly supervises the conditions of prisoners of war. The visit complied with the ICRC's normal work process and had nothing to do with any demand made by Cambodia, the statement said. The ICRC intended to witness the conditions the prisoners were being kept in and put them in communication with their respective families. The visit also showed Thailand strictly observes international humanitarian principles, especially the Geneva Convention of 1949, and transparently respects the human dignity of prisoners of war. The army said it let ICRC officials meet and talk freely with the captured Cambodian soldiers, without any time limit and without the presence of Thai officials and journalists, as the ICRC requested. The army also provided details of the prisoners' health examinations to the ICRC, showing the captured Cambodians were not tortured or mistreated. The army also informed the ICRC of the situations leading to the detention of 20 Cambodian soldiers and the treatment and repatriation of two of them. The 18 Cambodian soldiers were healthy and were not injured, the army statement said. They received three meals a day, stayed in a safe and hygienic place and were closely cared for by doctors.
